Steuber Holger, Zentgraf Matthias, La Motta Concettina, Sartini Stefania, Heine Andreas, Klebe Gerhard
Department of Pharmaceutical Chemistry, Philipps University Marburg, Marbacher Weg 6, 35032 Marburg, Germany.
J Mol Biol. 2007 May 25;369(1):186-97. doi: 10.1016/j.jmb.2007.03.021. Epub 2007 Mar 15.
Human aldose reductase (ALR2) has evolved as a promising therapeutic target for the treatment of diabetic long-term complications. The binding site of this enzyme possesses two main subpockets: the catalytic anion-binding site and the hydrophobic specificity pocket. The latter can be observed in the open or closed state, depending on the bound ligand. Thus, it exhibits a pronounced capability for induced-fit adaptations, whereas the catalytic pocket exhibits rigid properties throughout all known crystal structures. Here, we determined two ALR2 crystal structures at 1.55 and 1.65 A resolution, each complexed with an inhibitor of the recently described naphtho[1,2-d]isothiazole acetic acid series. In contrast to the original design hypothesis based on the binding mode of tolrestat (1), both inhibitors leave the specificity pocket in the closed state. Unexpectedly, the more potent ligand (2) extends the catalytic pocket by opening a novel subpocket. Access to this novel subpocket is mainly attributed to the rotation of an indole moiety of Trp 20 by about 35 degrees . The newly formed subpocket provides accommodation of the naphthyl portion of the ligand. The second inhibitor, 3, differs from 2 only by an extended glycolic ester functionality added to one of its carboxylic groups. However, despite this slight structural modification, the binding mode of 3 differs dramatically from that of the first inhibitor, but provokes less pronounced induced-fit adaptations of the binding cavity. Thus, a novel binding site conformation has been identified in a region where previous complex structures suggested only low adaptability of the binding pocket. Furthermore, the two ligand complexes represent an impressive example of how the slight change of a chemically extended side-chain at a given ligand scaffold can result in a dramatically altered binding mode. In addition, our study emphasizes the importance of crystal structure analysis for the translation of affinity data into structure-activity relationships.
人醛糖还原酶(ALR2)已逐渐成为治疗糖尿病长期并发症的一个有前景的治疗靶点。该酶的结合位点有两个主要亚口袋:催化阴离子结合位点和疏水特异性口袋。后者可处于开放或关闭状态,这取决于所结合的配体。因此,它表现出显著的诱导契合适应性能力,而催化口袋在所有已知晶体结构中都表现出刚性特征。在此,我们测定了分辨率为1.55 Å和1.65 Å的两种ALR2晶体结构,每种结构都与最近描述的萘并[1,2 - d]异噻唑乙酸系列抑制剂复合。与基于托瑞司他(1)结合模式的原始设计假设相反,两种抑制剂都使特异性口袋处于关闭状态。出乎意料的是,活性更强的配体(2)通过打开一个新的亚口袋扩展了催化口袋。进入这个新亚口袋主要归因于色氨酸20的吲哚部分旋转了约35度。新形成的亚口袋为配体的萘基部分提供了容纳空间。第二种抑制剂3与2的不同之处仅在于其一个羧基上添加了一个延长的乙醇酸酯官能团。然而,尽管有这种轻微的结构修饰,3的结合模式与第一种抑制剂的结合模式有很大不同,但引发的结合腔诱导契合适应性不太明显。因此,在一个先前的复合物结构表明结合口袋适应性较低的区域中,已鉴定出一种新的结合位点构象。此外,这两种配体复合物代表了一个令人印象深刻的例子,说明在给定配体支架上化学延伸侧链的微小变化如何导致结合模式发生显著改变。此外,我们的研究强调了晶体结构分析对于将亲和力数据转化为构效关系的重要性。